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Abstract
Pulmonary	veno-occlusive	disease	(PVOD)	and	pulmonary	capillary	haemangiomatosis	(PCH)	are	rare	disorders,	with	the	esti-
mated	prevalence	of	less	than	1	case	per	million	inhabitants.	The	vascular	pathology	in	PVOD/PCH	involves	pre-septal	and	septal	
veins,	alveolar	capillaries	and	small	pulmonary	arteries.	According	to	the	ERS/ESC	classification	of	pulmonary	hypertension	(PH)	
from	2015,	PVOD/PCH	have	been	included	in	the	subgroup	1’	of	pulmonary	arterial	hypertension	(PAH).	Recent	data	indicate,	how-
ever,	the	possibility	of	PVOD/PCH	pathology	in	the	patients	diagnosed	in	the	group	1.	The	problem	may	concern	PAH	associated	
with	scleroderma,	drug-	induced	PAH,	PAH	due	to	HIV	infection	and	up	to	10%	of	patients	with	idiopathic	PAH	(IPAH).	Recently,	
bi-allelic	EIF2AK4 mutations were	found	in	the	cases	with	heritable	form	of	PVOD/PCH	and	in	about	9%	of	sporadic	cases.	More-
over,	an	association	between	occupational	exposure	to	organic	solvents	and	PVOD/PCH	was	proved.	The	present	review	is	an	
attempt	to	summarise	the	current	data	on	pathogenesis,	risk	factors,	clinical	features	and	diagnostic	algorithm	for	PVOD/PCH.
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Introduction
Pulmonary veno-occlusive disease (PVOD) 
and pulmonary capillary haemangiomatosis (PCH) 
constitute the subgroup 1’ of pulmonary arterial 
hypertension (PAH) in the clinical classification 
of pulmonary hypertension (PH) (Table 1) [1]. 
PVOD and PCH were first described as two dis-
tinct diseases; recently, it has been suggested 
that PCH could be a  secondary process in the 
course of PVOD [2]. Histological examination of 
a  lung specimen remains the gold standard for 
a definitive diagnosis of PVOD/PCH, but it may 
be obtained only in the end-stage disease (from 
explanted lungs) or post-mortem, as lung biopsy 
is contraindicated in the setting of clinically sig-
nificant PH, due to high bleeding risk. 
The pathological data documented PVOD/PCH 
in PAH associated with CTD (mainly scleroderma) 
and with drug induced PAH. Moreover, PVOD/
PCH is believed to be an unrecognised cause of 
pulmonary hypertension in up to 10% of patients 
diagnosed with idiopathic PAH (IPAH) [1, 3]. The 
clinical course of disease in such patients may 
be different from typical group 1 patients: the 
response to PAH-specific drugs may be worse, oc-
casionally lung oedema in the course of PAH-spe-
cific therapy is noted. Due to poor life expectancy, 
such patients should be promptly qualified for 
lung transplantation. 
Therefore, an urgent need for a non-invasive 
diagnostic approach to PVOD/PCH recognition is 
required. Such approach, based on genetic coun-
selling and the results of clinical, pathophysio-
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logical, radiological, and bronchoalveolar lavage 
examinations, has been proposed recently [4, 5]. 
The present review is an attempt to summarise 
the data on pathogenesis, risk factors, clinical 
features and diagnostic algorithm for PVOD/PCH.
Pathology of PVOD/PCH
The vascular pathology in PVOD/PCH in-
volves pre-septal and septal veins, alveolar cap-
illaries and small pulmonary arteries (Figs 1, 2). 
Small pulmonary veins and venules become 
narrow or obliterated as a result of thrombosis, 
usually organised and seen as intensive intimal 
fibrosis. The veins become arterialised, i.e., 
the normal single layer of elastic fibres in vein 
walls is doubled or even tripled, mimicking 
pulmonary arteries. Sometimes elastic fibres can 
be encrusted with iron and calcium deposits. 
Reactive granulomas formed by multinucleated 
giant cells often surround such deposits [3]. 
Alveolar capillaries are changed due to down-
stream obstruction, with their dilatation and 
proliferation. This angioproliferative process is 
called PCH [2]. Pulmonary haemorrhages due to 
venous obstruction result in the accumulation of 
haemosiderin — laden macrophages. The inter-
Figure 1 A, B.	Pulmonary	veno-occlusive	disease.	A —	almost	totally	occluded	veins	are	seen	within	interlobular	septa	(arrows)	at	low	
magnification.	Surrounding	alveolar	spaces	show	hemorrhage;	B —	medium-power	magnification	of	one	of	the	veins:	the	 lumen	of	the	
vessel	(a space	inferiorly	to	the	black	stained	elastic	fiber	layer)	is	clearly	narrowed	and	filled	with	a fibrotic	tissue	(Elastic	van	Gieson	
stain,	magn.	×	40	(A)	and	200	(B)
stitial oedema or mild fibrosis of the interlobular 
septa is also seen [2]. 
Arterial lesions in PVOD/PCH are similar to 
PAH and include intimal fibrosis, medial hyper-
trophy and thrombotic occlusion; however, plexi-
form lesions typical of PAH are not present [2, 3].
PVOD/PCH pathology described above has 
been found either in the patients with isolated 
pulmonary vascular disease or in connection with 
other conditions such as: scleroderma [6], pul-
monary Langerhans cell histiocytosis (PLCH) [7] 
or rarely — sarcoidosis [8, 9]. Recently, PVOD/PCH 
was also reported in a patient with diffuse lung em-
physema and severe pulmonary hypertension [10]. 
Genetic alterations in PVOD/PCH
In 2014, bi-allelic, autosomal recessive muta-
tions of the eukaryotic translation initiation factor 
2alpha kinase 4 (EIF2AK4) gene were identified 
in the families with heritable PVOD by Eyries et 
al. [11]. EIF2AK4 mutation has been confirmed 
in all patients with heritable form of PVOD and 
in about 9% of sporadic cases [12]. Moreover, 
this type of genetic alteration was absent in the 
control group of PAH patients. Best et al. [13] 
also found EIF2AK4 mutation in the patients with 
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Figure 2 A–C.	Pulmonary	capillary	hemangiomatosis.	A —	at	low	power,	one	of	multiple	foci	of	“hyperemia-like	area”	can	be	noted	(circle);	B	—	at	
higher	power,	the	lesion	is	composed	of	irregular	in	shape,	dilated	capillary	structures	(arrow)	filed	with	blood	that	clearly	differ	from	normal	interal-
veolar	septa	(asterisk);	C —	the	same	area	as	in	B	—	immunohistochemical	reaction	to	CD34	highlights	the	endothelium;	compare	the	pathological	
(arrow)	and	normal	capillaries	(asterisk)	(A:	hematoxylin	and	eosin	staining,	magn.	×	40:	B:	hematoxylin	and	eosin	staining,	magn.	×	200;	C:	
anti-CD34	immunohistochemical	reaction,	magn.	×	200)	
familial occurrence of PCH [13]. The same type of 
mutation was identified by Tenorio et al. [14] in 
5 Iberian Gypsy families with an aggressive form 
of PAH that developed in a young age [14]. These 
families were of Gypsy-Romanic ethnicity, with 
high rate of co-sanguinity due to endogamy. The 
authors have not found any genetic alterations in 
TGF beta family in the above mentioned ethnic 
group [14].
Best et al. [15] found bi-allelic EIF2AK4 
mutations in 1 out of 9 hereditary PAH (hPAH) 
patients, and none of 72 IPAH patients.
Recently, Hadinnapola et al. [16] performed 
whole genome sequencing in 808 patients with IPAH, 
56 with hPAH and 16 patients with PVOD/PCH. 
Bi-allelic mutations of EIF2AK4 were identified 
in 5 PVOD/PCH patients and in 9 IPAH patients 
(1%). Interestingly, EIF2AK4 positive IPAH pa-
tients, investigated both by Best et al. [15] and 
by Hadinnapola et al. [16], exhibited clinical 
symptoms that might be indicative of PVOD/PCH.
Woerner et al. [17] reported on 9 cases of 
histologically confirmed PVOD in children (mean 
age 13.5 years, range 8–16 years). Unfortunately, 
mutation status was not investigated in them. 
Recently, Levy et al. [18] found EIF2AK4 mutation 
in 2 out of 3 children with PVOD presenting as 
severe refractory pulmonary precapillary hyper-
tension.
Occupational dependence of PVOD/PCH
In 2015, Montani et al. reported on the asso-
ciation between occupational exposure to organic 
solvents and PVOD [5]. A case control study con-
ducted among 33 consecutive PVOD patients and 
65 PAH patients as controls revealed significantly 
higher prevalence of occupational exposure to 
organic solvents in PVOD patients, compared 
to PAH patients (72.7% vs 27.7%, respectively). 
Exposure to trichloroethylene was significantly 
more frequent in PVOD compared to PAH (42% 
vs 3%, respectively) [5]. The trichloroethylene use 
was reported mostly by: metal workers, mecha-
nics and repairers, building painters and cleaners. 
Other exposures included degreasing agents, 
paints and varnish/glue. Occupational exposure 
to organic solvents was more frequent in men and 
in the older age group. The questionnaire also 
revealed a significantly higher tobacco exposure 
in PVOD compared to PAH patients (total pack-
years 33 ± 24.7 vs 8.0 ± 14.3 respectively) [5]. 
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PVOD/PCH in the course of other pathologies
PVOD/PCH may also be induced by chemo-
therapeutic agents and/or radiation. Ranchoux 
et al. [19] presented the summary of clinical 
findings in chemotherapy-induced, histologically 
confirmed PVOD. It was based on 10 cases from 
the French PH network and 27 cases published 
in the literature. PVOD occurred in the course of 
chemotherapy of both solid tumours (breast, lung, 
brain) and haematologic malignancies (Hodgkin 
and non-Hodgkin lymphoma, acute lympho-
blastic and myeloid leukaemia). Most patients 
received the regimens composed of several drugs, 
with alkylating agents use in 83.8% of cases, an-
timetabolites in 40.5%, plant alkaloids and other 
naturally occurring molecules in 45.9%, as well 
as cytotoxic antibiotics in 43.2% [19]. Alkylating 
drugs, most frequently related to PVOD develop-
ment included the following: cyclophosphamide, 
mitomycin C (MMC) and cisplatin, especially 
when combined with additional radiotherapy 
or allogenic steam cell transplantation [19]. The 
ability of cyclophosphamide to induce PH was 
confirmed by the authors in animal models [19]. 
Subsequently, the same group of authors report-
ed on 7 cases of chemotherapy-induced PVOD 
in patients with squamous cell anal carcinoma, 
who received MMC alone or in combination with 
5-fluorouracil [20]. 
Another causes of PVOD/PCH are HIV in-
fection and connective tissue diseases [1]. Dorf-
muller et al. analysed lung samples obtained 
post-mortem or from the explanted lungs of 
8 patients with PAH associated with CTD and 
29 IPAH patients [6]. Fibrous remodelling of 
pulmonary venules was found in 75% of cases 
of PAH associated with CTD and 17% of IPAH 
specimens. Scleroderma was the most frequent 
CTD linked with PAH. 
The group of conditions that can be associ-
ated with PVOD/PCH also includes interstitial 
lung diseases — PLCH [7] and sarcoidosis [8, 9], 
autoimmunological diseases such as Hashimo-
to’s  thyroiditis [21], haematopoetic stem cells 
transplantation [4] and other haematologic ma-
lignancies (polycythemia vera) [22].
Epidemiology
PVOD/PCH is a  rare disease, with the esti-
mated incidence rate of 0.2–0.5 cases per million 
inhabitants per year [1]. Nevertheless, the true 
incidence is possibly higher as 3–12% of cases 
classified as idiopathic PAH exhibit various 
clinical features suggestive of PVOD/PCH [1, 3]. 
In addition, the cases associated with other con-
ditions or drugs/toxins-induced are also missing 
in the statistics. 
Diagnosis of PVOD/PCH
Age and sex
Distribution of age at PVOD/PCH diagnosis 
is bimodal. The first peak is observed at the age 
of 20–30, and it probably reflects the genetic 
dependence of the disease. Montani et al. [23] 
compared phenotypes of PVOD with and without 
EIF2AK4 mutation. The mutation carriers were 
significantly younger compared to non-carriers 
(median age 26 vs 60 years, respectively) [23]. 
The second peak is observed at the age of 70–80, 
which is more typical of all the secondary causes 
of PVOD/PCH. The heritable cases are diagnosed 
with the same frequency among men and women, 
the occurrences associated with occupational 
exposures are more frequent in males than in 
females [23]. 
Clinical presentation
Clinical presentation of PVOD/PCH is in 
many aspects similar to PAH. Dyspnoea on exer-
tion, syncope and heart palpitations are common. 
Digital clubbing is more frequent in PVOD/PCH 
compared to PAH [1]. On auscultation, bi-basal 
crackles may be heard due to lung congestion, 
while they are unusual in PAH [1, 24]. 
Lung function, gas exchange and exercise testing 
The presence of lung congestion in addition 
to pulmonary hypertension in PVOD/PCH worsens 
the gas exchange in the lungs. Thus, PVOD/PCH 
patients present with more profound resting 
hypoxaemia, deeper exercise desaturation and 
lower lung diffusion capacity for carbon monox-
ide compared to PAH patients [1,24]. 
Radiological features of PVOD/PCH
The chest X-ray is of limited value, in the 
diagnostic algorithm for PVOD/PCH. High res-
olution computed tomography of the chest 
(HRCT) is the study of choice. It reveals the 
presence of three characteristic features of PVOD/
PCH: smooth thickening of interlobular septa, 
ill-defined centrilobular ground glass opacities 
and mediastinal lymph nodes enlargement [1] 
(Fig. 3A, B). 
Resten et al. [25] compared HRCT findings of 
15 patients with confirmed PVOD and 15 IPAH 
patients. They found ground glass opacifications 
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Figure 3A, B.	PVOD	in	35-year	old	man,	computed	tomography	of	the	chest	(CT);	A —	high	resolution	CT	image	(	lung	window	level)	shows	inter-
lobular	septal	thickening	and	diffuse	bilateral	patchy	ground	glass	opacities.	There	is	no	pleural	effusion	noted;	B	—	angio	CT	image	(mediastinal	
window	level)	shows	dilated	pulmonary	trunk	and	proximal	central	pulmonary	arteries	—	signs	of	pulmonary	hypertension
in 87% vs 33% cases, septal lines in 93% vs 13% 
of cases, and enlarged mediastinal lymph nodes in 
80% vs 0%, respectively [25]. All the differences 
were statistically significant. 
Gunther et al. [26] analysed retrospectively 
HRCT data from 26 systemic sclerosis (SSc) pa-
tients with precapillary PH and compared them 
to 28 SSc patients without PH or interstitial lung 
disease. They found lymph node enlargement in 
57.7% vs 3.6%, centrilobular ground glass opac-
ities in 46.6% vs 10.7% and septal lines in 88.5% 
vs 7.1% of the patients in these two groups respec-
tively [26]. All the differences were statistically 
significant. Moreover, in 61.5% of SSc patients 
with precapillary PH, at least two of radiologic 
features coexisted [26]. At present, the thickening 
of interlobular septa in HRCT is considered the 
most specific radiological feature of PVOD/PCH.
Ill-defined centrilobular ground glass opaci-
fications are probably most frequent, although 
less specific, because they are also occasionally 
observed in IPAH. In our own group of IPAH 
patients, centrilobular nodules as the only paren-
chymal lung abnormality on HRCT were found in 
19% of the cases [27]. Their presence was relat-
ed to the lower mean age, lack of the persistent 
foramen ovale, and the higher mean right atrial 
pressure compared to IPAH patients with no 
centrilobular nodules [27]. There is no consensus 
on the pathogenesis of centrilobular ground glass 
opacifications. Some authors state that they may 
be caused by the presence of cholesterol granulo-
mas due to occult pulmonary haemorrhage [28]. 
In PCH, centrilobular nodules may be dominating 
over other radiological signs [29]. Miura et al. [30] 
found that the centrilobular nodules in PCH are 
significantly larger than in PVOD [30]. 
Enlarged mediastinal lymph nodes develop 
as a result of venous lung congestion, veno-lym-
phatic shunts and angiogenic factors [31]. They 
are usually observed in combination with other 
radiological features of PVOD/PCH [26]. De 
Montpreville et al. [31] reviewed pulmonary 
and mediastinal lymph nodes resected during 
lung transplantation in 19 PVOD/PCH patients 
and found lymphatic congestion, vascular trans-
formation of the sinuses, intra-sinusal haemor-
rhage and lymphoid follicular hyperplasia [31]. 
The presence of at least two from the above 
mentioned features on HRCT study of the lungs 
rises suspicion of PVOD/PCH, and the existence 
of all three findings has 100% specificity and 66% 
sensitivity for PVOD/PCH in cases of PAH [1]. 
Lung scintigraphy as diagnostic tool in PVOD/PCH
The guidelines recommend the use of 
ventilation-perfusion lung scintigraphy in 
the differential workup of PH to differentiate 
between PAH and chronic thromboembolic 
pulmonary hypertension (CTEPH) [1]. The 
presence of unmatched segmental perfusion 
defects is typical of CTEPH, but not of PAH. Ac-
cording to some authors, multiple unmatched 
segmental perfusion defects may be also found 
in PVOD patients [32]. Nevertheless, recent 
retrospective double blind analysis performed 
in 70 IPAH/hPAH and 56 PVOD patients, do-
cumented unmatched perfusion defects in 10% 
of IPAH and 7% of PVOD patients [33]. Thus, 
according to the present state of knowledge, the 
ventilation-perfusion scans are not helpful in 
distinguishing PAH from PVOD/PCH, although 
they are still very important to distinguish 
CTEPH from PAH [1]. 
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Table 1. Current classification of pulmonary hypertension [1]
1.	Pulmonary	arterial	hypertension
	 1.1.	Idiopathic	PAH
	 1.2.	Heridable	PAH
	 	 1.2.1.	BMPR2
	 	 1.2.2.	ALK-1,	ENG,	SMAD	9,	CAV1,	KCNK3
	 	 1.2.3.	Unknown
	 1.3.	Drug	and	toxin	induced
	 1.4.	Associated	with:
	 	 1.4.1.	Connective	tissue	disease
	 	 1.4.2.	HIV	infection
	 	 1.4.3.	Portal	hypertension
	 	 1.4.4.	Congenital	heart	disease
	 	 1.4.5.	Schistosomiasis
1’	Pulmonary	veno-occlusive	disease	and/or	pulmonary	capillary	hemangiomatosis
	 1’.1.	Idiopathic
	 1’.2.	Heritable
	 	 1’.2.1.	EIF2AK4	mutation
	 	 1’2.2.	Other	mutations
	 1’.3.	Drugs,	toxins	and	radiation	induced
	 1’.4.	Associated	with:
	 	 1’.4.1.	Connective	tissue	disease
	 	 1’.4.2.	HIV	infection
	I”	Persistent	pulmonary	hypertension	of	the	newborn	(PPHN)
2.	 Pulmonary	hypertension	due	to	left	heart	disease
	 2.1.	Left	ventricular	systolic	dysfunction
	 2.2.	Left	ventricular	diastolic	dysfunction
	 2.3.	Valvular	disease
	 2.4.	Congenital/acquired	left	heart	inflow/outflow	tract	obstruction	and	congenital	cardiomyopathies
3.	 Pulmonary	hypertension	due	to	lung	diseases	and/or	hypoxia
	 3.1.	Chronic	obstructive	pulmonary	disease
	 3.2.	Interstitial	lung	disease
	 3.3.	Other	pulmonary	diseases	with	mixed	restrictive	and	obstructive	pattern
	 3.4.	Sleep-disordered	breathing
	 3.5.	Alveolar	hypoventilation	disorders
	 3.6.	Chronic	exposure	to	high	altitude
	 3.7.	Developmental	lung	diseases
4.	 Chronic	thromboembolic	pulmonary	hypertension	(CTEPH)	and	other	pulmonary	artery	obstructions
5.	 Pulmonary	hypertension	with	unclear	multifactorial	mechanisms
	 5.1.	Hematologic	disorders:	chronic	hemolytic	anemia,	myeloproliferative	disorders,	splenectomy
	 5.2.	Systemic	disorders:	sarcoidosis,	pulmonary	histiocytosis,	lymphangioleiomyomatosis
	 5.3.	Metabolic	disorders:	glycogen	storage	disease,	Gaucher	disease,	thyroid	disorders,	
	 5.4.	Others:	tumoral	obstruction,	fibrosing	mediastinitis,	chronic	renal	failure,	segmental	PH
BMPR:	bone	morphogenic	protein	receptor	type	II;	CAV1:	caveolin-1;	ENG:	endoglin;	EIF2AK4:	eukaryotic	translation	initiation	factor	2	alpha	kinase	4;	HIV:	human	
immunodeficiency	virus;	PAH:	pulmonary	arterial	hypertension
Bronchoalveolar lavage
Occult alveolar haemorrhage may happen 
in PVOD/PCH due to capillary pathology and 
lung congestion. The proof of this concept was 
published by Rabiller et al. [34] who found the 
increased percentage of haemosiderin — laden 
macrophages in bronchoalveolar lavage fluid 
(BALF) of PVOD patients compared to PAH pa-
tients (40 ± 37% vs 3 ± 6%) [34]. The intensity 
of haemosiderin staining per 100 macrophages 
(Golde score) was calculated as 81 ± 88 in PVOD 
and 4 ± 10% in PAH [34].
The induced sputum Golde score was also 
found to be diagnostic tool in the patients with 
PVOD suspicion by Lederer et al. [35]. The au-
thors proposed the Golde score of 200 as the 
cut off value indicating the possibility of occult 
alveolar haemorrhage [35]. The validation of this 
method in PVOD diagnosis has not been provided 
yet; nevertheless, it is promising in the patients 
with severe hypoxaemia, who are at high risk of 
bronchoscopy complications.
Haemodynamic evaluation
Right heart catheterisation (RHC) is manda-
tory for the recognition of PAH. As PVOD/PCH 
involves small pulmonary veins, pulmonary 
artery wedge pressure remains usually below 
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15 mm Hg. Thus, PVOD/PCH patients fulfil the 
criteria of precapillary PH [3]. Nevertheless, due 
to increased pressure in small pulmonary veins 
and capillaries, lung oedema may develop in the 
course of acute vasoreactivity testing on RHC or 
after the introduction of PAH-specific therapy 
[1, 3]. In a case-series published by Montani et 
al., lung oedema in the course of PAH-specific 
therapy was observed in 21–23% of patients with 
PVOD/PCH [23].
Recommended PVOD diagnostic criteria
New PVOD diagnostic algorithm was propo-
sed recently by Montani et al. [5]. The authors 
introduced subsequent definitions: 
Confirmed PVOD
1. The presence of characteristic pathological 
features in the lung tissue obtained from the 
explanted lung or on post-mortem examination.
2. The presence of a bi-allelic EIF2AK4 muta-
tion in the patients with pulmonary arterial 
hypertension.
3. Pulmonary oedema following the introduc-
tion of PAH-specific therapy in the patient 
with clinical signs of highly probable PVOD.
Highly probable PVOD
The patients fulfilling at least two of the 
following criteria:
1. Two or more characteristic radiological signs 
of PVOD described on HRCT (septal lines, 
centrilobular ground glass opacities, enlarged 
mediastinal lymph nodes).
2. Diffusing capacity of the lung for carbon 
monoxide to alveolar volume ratio DLCO/
VA < 55% or resting arterial oxygen tension 
(PaO2) < 65 mm Hg.
3. The presence of alveolar haemorrhage on 
BALF with the Golde score > 80% or hae-
mosiderin-laden macrophages > 30%. 
Differential diagnosis
Taking into account previously described 
difficulties in distinguishing between PAH and 
PVOD as well as potential overlap within both 
conditions, it is justifiable that all patients diag-
nosed with PAH should be carefully screened for 
the possibility of PVOD. 
The differences between PAH and PVOD are 
summarised in Table 2. 
Table 2.  Differential diagnosis between pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension 
(PAH), based on Montani et al. [3]
Factor PVOD PAH
Genetics EIF 2AK4
Autosomal	recessive
BMPR2, ACVRL1, ENG, KCNK3, CAV-1, SMAD 9
Autosomal	dominant
Sex No	sex	predominance	in	familial	PVOD,	males	predo-
minance	in	occupationally	induced	PVOD
Females	predominance
Smoking Frequent Not	frequent
Occupational	exposure Organic	solvents None
Other	risk	factors Alkylating	agents,	radiotherapy Anorexigens,	toxic	rapeseed	oil,	dasatinib,	selective	
serotonin	re-uptake	inhibitors
Other	associated	conditions CTD,	Hashimoto	thyroiditis CTD,	HIV,	CHD,	portal	PAH
Auscultatory	cracles present Absent	(	in	IPAH)
DLCO Often	severe	reduction Mild	reduction
Resting	PaO2 Often	severe	reduction Mild	reduction
Desaturaion	on	6MWT Often	significant Usually	mild
Chest	CT Centrilobular	ground	glass	opacities,	septal	lines,	
mediastinal	lymph	nodes	enlargement
Usually	no	parenchymal	abnormalities	(IPAH)
BALF Possible	hemosiderin	laden	macrophages Normal
Targeted	PAH	therapy Risk	of	pulmonary	oedema Improved	FC	and	heamodynamics
Prognosis Poor Dependent	on	FC	and	haemodynamics
EIF2AK4:	eukaryotic	translation	initiation	factor	2alpha	kinase	4;	BMPR2:	bone	morphogenetic	protein	receptor	type	II;	ACVRL1:	activin	receptor-like	kinase	1;	ENG:	
endoglin;	KCNK3:	potassium	channel	subfamily	K member	3;	CAV-1:	caveolin	1;	SMAD	9:	mothers	against	decapentaplegic	homolog	9;	CTD:	connective	tissue	disease;	
HIV:	human	immunodeficiency	virus;	CHD:	congenital	heart	disease;	DLCO:	diffusing	capacity	of	the	lung	for	carbon	monoxide;	PaO2:	arterial	oxygen	partial	pressure;	
6MWT:	6-minute	walk	test;	CT:	computed	tomography;	IPAH:	idiopathic	pulmonary	arterial	hypertension;	BALF:	bronchoalveolar	lavage	fluid;	FC:	functional	class
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Table 3.  Differential diagnosis between pulmonary venoocclusive disease (PVOD), hypersensitivity pneumonitis (HP) and 
sarcoidosis (BBS)
Factors PVOD HP BBS
Factors	involved	in	path-
ogenesis
Exposure	to	organic	solvents,	alkyla-
ting	agents,	radiotherapy
Recurrent	exposure	to	overt	or	
occult	environmental	antigens
Not	known	(mycobacterial,	bacterial	
antigens?)
Clinical	picture Lung	disease Lung	disease Possible	multi-organ	disease
Auscultation
bi-basal	crackles
wheezing
Present
Absent
Present
Sometimes	present
Sometimes	present
Possible
Plethysmography Normal Restrictive	lung	pattern,	occa-
sionally	hyperinflation	and/or	
obstruction
Restrictive	lung	pattern,	occasional-
ly	obstruction
DLCO Severe	reduction Reduced Reduced
Chest	CT Centrilobular	ground-glass	opacities,	
septal	lines,	mediastinal	lymph	nodes	
enlargement
Diffuse	centrilobular	micro-
nodular	pattern,	ground	glass	
opacification,	air-trapping,		
fibrosis,	occasionally		
mediastinal	lymphadenopathy
Micronodular	pattern,	localisation	
along	the	broncho-vascular	bundles,	
mediastinal	and	hilar	lymph	nodes	
enlargement
BALF Possible	hemosiderin-laden	macro-
phages
Lymphocytosis	>	25%	(usually	
higher)
Lymphocytosis	>	25%
Serum	markers None Specific	IgG	antibodies	(pre-
cipitins)	to	environmental	
antigens
ACE
Pulmonary	hypertension	
on	RHC
Severe	precapillary Mild	precapillary	—	in	end-	
stage	disease
Mild	precapillary	—	mostly	in		
stage	IV
Possibility	of	post-capillary	PH	due	
to	heart	involvement	or	mediastinal	
fibrosis
Prognosis Poor Dependent	on	the	possibility	
of	elimination	of	responsible	
antigen
Dependent	on	disease	stage,	
presence	of	PH	and	type	of	organ	
involved
DLCO:	diffusing	capacity	of	the	lung	for	carbon	monoxide;	CT:	computed	tomography;	BALF:	bronchoalveolar	lavage	fluid;	IgG:	immunoglobulin	G;	ACE:	angiotensin-
converting	enzyme;	PH:	pulmonary	hypertension
Findings on lung HRCT in PVOD/PCH have 
to be differentiated from interstitial lung disease. 
The morphology of centrilobular ground glass 
opacities seen in PVOD/PCH in HRCT is similar to 
that seen in hypersensitivity pneumonitis (HP) [29, 
36]. However, HP has other typical radiological fea-
tures not seen in PVOD/PCH such as mosaic lung 
attenuation, air trapping or lung fibrosis [37, 38]. 
Moreover, in most cases HP may be excluded bas-
ing on the lack of characteristic elements such as: 
a history of exposure to organic dusts, restrictive 
pattern on body plethysmography, and lymphocy-
tosis in BALF [37, 38]. The details of differential 
diagnosis between HP and PVOD/PCH are listed 
in Table 3. Respiratory bronchiolitis-associated 
interstitial lung disease (RB-ILD) and PLCH have 
to be also taken into account in the patients with 
centrilobular ground glass nodules [39].
The thickening of the interlobular septa and 
lymphadenopathy seen in PVOD/PCH may re-
quire the differential diagnosis with sarcoidosis; 
nevertheless, in PVOD/PCH the septa thickening 
is smooth and localised in subpleural region, 
while in sarcoidosis the thickening is nodular 
due to the accumulation of nodules along the 
bronchovascular bundles [40]. The details of 
differential diagnosis are listed in Table 3.
Therapy and prognosis
The introduction of PAH-specific therapy 
in PVOD/PCH patient may result in the acute 
clinical worsening due to lung congestion. Such 
complications have been observed in 20–50% 
of PVOD/PCH patients undergoing PAH-specific 
therapy [3, 23, 41], and even in 75% of PVOD/
PCH patients receiving calcium channel blockers 
[3]. The development of lung oedema is caused 
by the vasodilatation of pulmonary arterioles, 
with an increase of trans-capillary hydrostatic 
pressure due to augmented blood flow in fibrotic 
post-capillary venules. 
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Resten et al. [42] evaluated the results of 
epoprostenol therapy in 73 patients with severe 
PH. In 12 patients with radiological picture that 
might be suggestive of PVOD/PCH, the adverse 
clinical response to epoprostenol was observed. 
In 6 of them PVOD was confirmed on pathologic 
examination. 
Nevertheless, the use of epoprostenol at 
a  low dose, with slow up-titration and with 
a high dose of loop diuretics to prevent pulmonary 
oedema resulted in mild clinical improvement or 
stabi lisation of the disease in 12 patients with 
severe PVOD, listed for lung transplantation [43]. 
Similar observation was published by Ogawa et al. 
[44] who treated 8 PVOD/PCH patients with epo-
prostenol (maximum dose 55.3 ± 10.7 ng/kg/min). 
The therapy significantly decreased brain natri-
uretic peptide (BNP) level, improved 6-min walk 
distance as well as cardiac index; nevertheless, 
pulmonary artery pressure and pulmonary vascu-
lar resistance did not change significantly. 
An interesting case report concerning diffe-
rent efficacy of several PAH-specific drugs in the 
patient with MMC-induced PVOD/PCH (in the 
course of the treatment of peritoneal cancer) was 
reported by Koyama et al. [45]. The introduction 
of sildenafil (20 mg/day) caused pulmonary oede-
ma, but a subsequent use of bosentan, at a low 
dose at the beginning and then increasing up to 
250 mg/day, with tadalafil (20 mg) as add- on the-
rapy, brought clinical improvement. The patient 
died of disseminated neoplastic disease after 
several months and post-mortem examination 
confirmed PVOD/PCH.
Thus, even if stabilisation of the disease or 
mild clinical improvement are observed in the 
course of the first line therapy in PVOD/PCH, the 
treatment goals are usually not achieved. On the 
other hand, life-threatening lung oedema may 
be observed in the patients listed for sequential 
add-on therapy with PAH-specific drugs after 
inadequate response to first-line drug [46]. 
In accordance with a  general opinion of 
experts, a  cautious use of specific PAH thera-
py could be proposed to patients with suspec-
ted PVOD and careful monitoring must be im-
plemented, but only at centres with extensive 
experience in the management of PH. The pa-
tients should be fully informed about the risks. 
Due to lack of effectiveness of PAH-specific tre-
atment in PVOD/PCH, several authors tried to 
investigate the role of anti-proliferative therapy 
in this group of patients. 
The most scrutinised drug in refractory PAH 
was tyrosine-kinase inhibitor — imatinib [47, 
48]. The use of imatinib as an add-on therapy in 
advanced PAH treated with at least two PAH-spe-
cific drugs was associated with the occurrence 
of fatal subdural haematomas, and the drug was 
not approved for refractory PAH therapy [47, 48]. 
Recently, Ogava et al. [49] reported on ima-
tinib as add-on therapy, at a dose of 100–400 mg/
day, in 9 PVOD/PCH patients, and compared the 
results with 7 PVOD/PCH patients who did not 
receive the drug [49]. Imatinib resulted in the 
significant improvement of the World Health 
Organisation (WHO) functional class and serum 
BNP concentration, as well as in the decrease of 
mean pulmonary artery pressure and prolonged 
survival [49]. The authors did not observe the 
development of subdural haematomas, but two 
patients in the imatinib-treated group died of 
infective complications. Nevertheless, median 
survival in the group treated with imatinib was 
over 4 years, which is unusual for PVOD/PCH 
patients [49]. 
The prognosis of PVOD/PCH patients is poor, 
due to relative unresponsiveness to treatment and 
fast progression of the disease. Rapid develop-
ment of the condition is observed especially in 
the patients with two or more radiological signs 
of PVOD/PCH [26, 50]. 
The only proved effective mode of therapy 
is bilateral lung transplantation [1]. Wille et al. 
[51] compared 6-month survival of PVOD/PCH 
patients and PAH patients remaining on the lung 
transplantation waiting list [51]. The death rate 
was 22.6% vs 11.0% respectively, indicating that 
patients with PVOD/PCH are at higher risk of de-
ath while on the transplant waiting list [51]. Thus, 
current guidelines recommend early listing for 
lung transplantation of the patients with newly 
recognised or highly probable PVOD/PCH [1]. 
Conclusions
PVOD/PCH is a rare disease causing severe 
PH. It may be an idiopathic as well as related to 
other conditions disease. Genetic and environ-
mental factors connected to the development 
of the disease have been identified. Diagnosis 
should be based on a combination of clinical 
observations, physical examination, bronchosco-
py and radiological findings. In heritable cases, 
the presence of a bi-allelic EIF2AK4 mutation is 
enough to confirm the diagnosis. The prognosis 
in PVOD/PCH is very poor. The patients should 
be cared for in experienced PH centres. Bilateral 
lung transplantation is the only effective therapy, 
and all eligible PVOD/PCH patients should be 
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referred to a transplant centre for evaluation as 
soon as the diagnosis is made. 
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